{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:17Z","timestamp":1787008757391,"version":"build-2736575974"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,14]]},"DOI":"10.1093\/eurheartj\/eht135","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T23:34:41Z","timestamp":1366241681000},"page":"2464-2471","source":"Crossref","is-referenced-by-count":176,"title":["Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial"],"prefix":"10.1093","volume":"34","author":[{"given":"Sana M.","family":"Al-Khatib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Flaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"key":"key\n\t\t\t\t20170626082809_EHT135C1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082809_EHT135C2","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082809_EHT135C3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.STR.27.10.1765","article-title":"Acute stroke with atrial fibrillation. The Copenhagen Stroke Study","volume":"27","author":"J\u00f8rgensen","year":"1996","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082809_EHT135C5","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1161\/STROKEAHA.111.625392","article-title":"Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry","volume":"42","author":"Lopes","year":"2011","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082809_EHT135C6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/archinte.1996.00440040024003","article-title":"Paroxysmal atrial fibrillation. A common but neglected entity","volume":"156","author":"Aboaf","year":"1996","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/01.STR.17.4.622","article-title":"Embolic complications in paroxysmal atrial fibrillation","volume":"17","author":"Petersen","year":"1986","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082809_EHT135C8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(99)00489-1","article-title":"Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators","volume":"35","author":"Hart","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626082809_EHT135C9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation\u2014Executive Summary","volume":"48","author":"ACC\/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626082809_EHT135C10","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","article-title":"2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"123","author":"ACCF\/AHA Task Force","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082809_EHT135C11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","article-title":"Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082809_EHT135C12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2796.2007.01909.x","article-title":"Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation","volume":"264","author":"SPORTIF Investigators","year":"2008","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-011-0230-1","article-title":"Promise of factor Xa inhibition in atrial fibrillation","volume":"14","author":"Al-Khatib","year":"2012","journal-title":"Curr Cardiol Reports"},{"key":"key\n\t\t\t\t20170626082809_EHT135C17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for stroke prevention in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170626082809_EHT135C18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626082809_EHT135C19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/j.1538-7836.2007.02610.x","article-title":"Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms","volume":"5","author":"van Leeuwen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170626082809_EHT135C20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082809_EHT135C21","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jacc.2007.07.076","article-title":"Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy","volume":"50","author":"Hohnloser","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626082809_EHT135C22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2011.10.896","article-title":"Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Study","volume":"59","author":"Flaker","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626082809_EHT135C23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/31\/2464\/17896031\/eht135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T15:36:22Z","timestamp":1562945782000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/eht135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":23,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2013,4,17]]},"published-print":{"date-parts":[[2013,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht135","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,17]]}}}